CFO transition
Ovid Therapeutics Inc. CFO transition: Charles Carter to succeed Jeffrey Rona
Ovid Therapeutics Inc. reported in a Form 8-K filed July 8, 2026 that Charles Carter will succeed Jeffrey Rona as Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective July 6, 2026.
In the filing's words
the Company’s Board of Directors (the “Board”) appointed Charles Carter, the Company’s Senior Vice President of Finance and Financial Planning, as the Company’s Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective as of the Separation Date.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Ovid Therapeutics Inc. (OVID) |
|---|---|
| Event | Transition |
| Incoming | Charles Carter |
| Outgoing | Jeffrey Rona |
| Title in the filing | Chief Financial Officer, principal financial officer, principal accounting officer and secretary |
| Effective | July 6, 2026 |
| 8-K filed | July 8, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Senior Vice President of Finance and Financial Planning, Ovid Therapeutics Inc. |
| SEC CIK | 0001636651 |
Ovid Therapeutics Inc. reported this change in a Form 8-K, Item 5.02, filed July 8, 2026. The filing's own words are quoted above.
Other records naming Jeffrey Rona
1The outgoing officer on this record, matched by name. Career line.
2026-03-18 · 10-K signature
Jeffrey Rona signed Ovid Therapeutics Inc.'s annual report as Chief Business and Financial Officer (Principal Financial and Accounting Officer)
Same industry, July 2026
7Other moves filed that month at companies the roster files under SIC “Pharmaceutical Preparations”.
3 months ago· 2026-07-31AppointmentGCAN
The Greater Cannabis Company, Inc. appoints Michelle Cervantes Vivanco as CFO
3 months ago· 2026-07-28TransitionVYNE
Yarrow Bioscience, Inc. CFO transition: Tyler Zeronda to succeed Mutya Harsch
3 months ago· 2026-07-22InterimKROS
Keros Therapeutics, Inc. names Annita Tanini interim CFO
3 months ago· 2026-07-20AppointmentPMHS
Polomar Health Services, Inc. appoints Douglas Beck as CFO
4 months ago· 2026-07-13AppointmentMBX
MBX Biosciences, Inc. appoints John Smither as CFO
4 months ago· 2026-07-06TransitionLGVN
Longeveron Inc. CFO transition: Marie Washburn to succeed Lisa Locklear
4 months ago· 2026-07-06AppointmentOGEN
Oragenics, Inc. appoints John Spencer as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Charles Carter? Send a correction with the primary source.